Free Trial
→ How to claim a stake in SpaceX before the June 12 IPO (From Brownstone Research) (Ad)tc pixel
NASDAQ:PHVS

Pharvaris Q2 2024 Earnings Report

Pharvaris logo
$29.47 -0.41 (-1.37%)
Closing price 05/27/2026 04:00 PM Eastern
Extended Trading
$31.62 +2.16 (+7.31%)
As of 05/27/2026 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pharvaris EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.57
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Pharvaris Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pharvaris Announcement Details

Quarter
Q2 2024
Date
8/14/2024
Time
N/A
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Pharvaris' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Pharvaris' Q2 2024 Press ReleasePress Release
(8-K)

Pharvaris Earnings Headlines

Pharvaris (NASDAQ:PHVS) CFO David Nassif Sells 10,000 Shares of Stock
May 27 at 5:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30804180
Pharvaris (NASDAQ:PHVS) Director Viviane Monges Sells 9,667 Shares of Stock
May 27 at 5:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30804179
The math on the SpaceX IPO is broken
SpaceX is expected to go public at a $1.75 trillion valuation. For investors to see a 10x return, the company would have to reach $17.5 trillion - more than Apple, Microsoft, and Nvidia combined. But there may be a smarter play: a tiny supplier, just 1/60th the size of SpaceX, has already shipped 5 billion critical components to the company over the last decade. Once SpaceX goes public this June, Wall Street analysts will likely tear through the supply chain and put this under-the-radar vendor on the map. Get the full details on this overlooked supplier before the June IPO.tc pixel
 |  Weiss Ratings (Ad)
Pharvaris (NASDAQ:PHVS) Insider Anna Nijdam Sells 5,501 Shares of Stock
May 27 at 4:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30803716
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Moderate Buy" from Brokerages
May 27 at 4:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30803358
Pharvaris (NASDAQ:PHVS) Director Sells $293,200.00 in Stock
May 25 at 5:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30799696
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies.

Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization.

Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.

View Pharvaris Profile
Earnings Tools